Can vitreous reflux affect the short-term treatment response after intravitreal ranibizumab injection

Basit Öğe Kaydı
dc.authorid0000-0003-2544-3580
dc.authorid0000-0003-4468-3985
dc.contributor.authorUyar, Enes
dc.contributor.authorUlaş, Fatih
dc.contributor.authorAlkan, Yunus
dc.date.accessioned2022-05-18T06:15:32Z
dc.date.available2022-05-18T06:15:32Z
dc.date.issued2020
dc.departmentTıp Fakültesi
dc.description.abstractThe aim of this study was to evaluate the effect of vitreous reflux (VR) on the short-term effect of intravitreal ranibizumab injection. Materials and Methods: The study included 181 eyes of 81 age-related macular degeneration (AMD) and 100 diabetic macular edema (DME) patients. Treatment response was evaluated by measuring central macular thickness (CMT) as well as 1 mm and 3 mm central macular thicknesses (MT1 and MT3). Patients were grouped as; Group 1: no VR, Group 2: [removed]3 mm VR according to conjunctival bleb diameters. The data were analyzed using variance, correlation and regression analyses. Results: In AMD patients, reduction of CMT values following the treatment were 88.3 ± 110.6 µm in Group 1, 85.6 ± 158.7 µm in Group 2, and 93.1 ± 92.2 µm in Group 3. Likewise, in DME patients, it was 82.4 ± 88.4 µm, 72.9 ± 109.9 µm, and 73.7 ± 113.7 µm, respectively. Reduction of MT1 values after the treatment were 47.4 ± 72.6 µm, 36.0 ± 131.9 µm, and 36.7 ± 114.4 µm in AMD patients, and 33.3 ± 72.5 µm, 36.6 ± 90.2 µm, and 46.9 ± 83.4 µm in DME patients. In all comparisons among groups of VR, macular thickness (MT) change did not exhibit significant difference following an intravitreal ranibizumab treatment (p > .05). Conclusion: We found that the increase in VR amount did not adversely affect the decrease in MT after intravitreal ranibizumab treatment in AMD and DME patients.
dc.identifier.doi10.1080/02713683.2020.1789664
dc.identifier.endpage254en_US
dc.identifier.issn0271-3683
dc.identifier.issue-en_US
dc.identifier.pmid32635750
dc.identifier.scopusqualityQ1
dc.identifier.startpage248en_US
dc.identifier.urihttps:/dx.doi.org/10.1080/02713683.2020.1789664
dc.identifier.urihttps://hdl.handle.net/20.500.12451/9401
dc.identifier.volume-en_US
dc.identifier.wosWOS:000547658000001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherTaylor and Francis Ltd.
dc.relation.ispartofCurrent Eye Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAge-related Macular Degeneration
dc.subjectDiabetic Macular Edema
dc.subjectIntravitreal Ranibizumab
dc.subjectMacular Thickness
dc.subjectTreatment Response
dc.subjectVitreous Reflux
dc.titleCan vitreous reflux affect the short-term treatment response after intravitreal ranibizumab injection
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
uyar-enes-2020.pdf
Boyut:
4.87 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu